Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Location: Belgium, Walloon Brabant, Corbais
Employees: 51-200
Founded date: 2007
Investors 2
| Date | Name | Website |
| - | Mayo Clini... | ventures.m... |
| - | Le Groupe ... | sriw.be |
Mentions in press and media 24
| Date | Title | Description | Source |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID... | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of ... | einpresswi... |
| 21.11.2023 | Publication of a transparency notification received from For... | MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (... | einpresswi... |
| 14.11.2023 | Information on the Total Number of Voting Rights and Shares ... | MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the... | einpresswi... |
| 17.03.2023 | Celyad Oncology to announce full year 2022 financial results... | /EIN News/ -- MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euron... | einpresswi... |
| 24.06.2022 | Celyad Oncology Announces Leadership Updates | MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Na... | globenewsw... |
| 22.12.2021 | Celyad Oncology Announces January 2022 Conference Schedule | MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Na... | globenewsw... |
| 17.12.2021 | Transparency notification received from Tolefi SA and relate... | MONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Na... | globenewsw... |
| 16.12.2021 | Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79... | KEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in patients with mic... | marketscre... |
| 15.12.2021 | Transparency notification received from Fortress Investment ... | MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Na... | globenewsw... |
| 09.12.2021 | Celyad Oncology Announces Closing of $32.5 Million Private P... | MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Na... | marketscre... |
Show more